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Background:We studied whether weight loss by intra-
gastric balloon would predict the outcome of subse-
quent gastric banding with regard to weight loss and
BMI reduction.
Methods: A prospective cohort of patients with a
body mass index (BMI) >40 kg/m2 received an intragas-
tric balloon for 6 months followed by laparoscopic
adjustable gastric banding (LAGB). Successful balloon-
induced weight loss was defined as ≥10% weight loss
after 6 months. Successful surgical weight loss was
defined as an additional 15% weight loss in the follow-
ing 12 months. Patients were divided in group A, losing
≥10% of their initial weight with 6 months’ balloon treat-
ment, and group B, losing <10% of their initial weight.
Results: In 40 patients (32 female, 8 male; age 36.6 yr,
range 26-54), the mean BMI decreased from 46.5 to 40.5
kg/m2 (P<0.001) after 6 months of balloon treatment and
to 35.2 kg/m2 (P<0.001) 12 months after LAGB. Group A
(25 patients) and group B (15 patients) had a significant
difference in BMI decrease, 12.4 vs 9.0 kg/m2 (P<0.05),
after the total study duration of 18 months. However,
there was no difference in BMI reduction (4.7 kg/m2 vs
5.8 kg/m2) in the 12 months after LAGB. 6 patients in
group A lost ≥10% of their starting weight during 6
months balloon treatment as well as ≥15% 12 months
following LAGB. 6 patients in group B lost <10% of their
starting weight after 6 months of BIB, but also lost ≥15%
12 months following LAGB.
Conclusion: Intragastric balloon did not predict the
success of subsequent LAGB.
Key words: Morbid obesity, intragastric balloon, laparo-
scopic gastric banding
Introduction
The modern lifestyle of increased food consumption
and sedentary activities has resulted in a global epi-
demic of obesity. Morbid obesity is associated with
serious health problems, including cardiovascular
disease, hypertension, diabetes type 2, hyperlipi-
demia, sleep apnea syndrome, osteoarthritis, certain
neoplasms, psychosocial disabilities and impaired
quality of life. Conservative treatments with diets and
medication are successful in the short term, but dur-
ing long-term follow-up, the relapse rate is high after
the treatment is discontinued; >90% of the patients
are back to their starting weights within 5 years.1,2
In the 1980s, intragastric balloon treatment was
introduced, with satisfactory short-term effects at 6
months, but with balloon removal, patients relapsed
to their original weight or even higher – the weight
cycling effect.3,4 Morbid obesity (body mass index
>40 kg/m2 or >35 kg/m2 with co-morbidity) seems to
be very treatment-resistant by conservative therapy,
but long-term results are achieved with bariatric sur-
gery,5 including restrictive procedures resulting in
decreased oral intake and malabsorptive procedures
resulting in decreased intestinal absorption. 
Laparoscopic adjustable gastric banding (LAGB)
has been proven to be safe, easily reversible and is
adjustable; this restrictive procedure generally has a
low morbidity and results in satisfactory weight loss,
at least in short-term follow-up.6-9 Yet, a substantial
number of patients fail to respond in the long-term,
which is why laparoscopic gastric bypass is gaining
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interest.10,11 Therefore, a selection instrument that
may be used to determine which patient would
respond to gastric restrictive or malabsorptive surgery,
is needed. Some authors have applied the “balloon-
test”, because it was suggested that patients who
demonstrate good short-term weight loss after balloon
treatment may continue weight loss after LAGB.12 In
the super-obese, some surgeons perform a long-limb
gastric bypass or biliopancreatic diversion at the out-
set. This signifies a major operation in a group of
patients in whom some might have benefit from gas-
tric banding, even if a malabsorptive procedure may
later be needed. They then could have a lower weight
to undergo the second intervention.13-15
Therefore we decided to investigate prospectively
if and to what extent the preoperative placement of
a gastric balloon could be used to better select mor-
bidly obese patients for bariatric operations.
Patients and Methods
Patients
Consecutive patients referred for bariatric surgery
were asked to participate in a prospective study,
consisting of 6 months of intragastric balloon treat-
ment followed by gastric banding. Patients were
screened by a multidisciplinary team consisting of a
surgeon, dietician, gastroenterologist and psycholo-
gist. The inclusion criteria of the NIH16 were fol-
lowed (Table 1) and patients signed informed con-
sent. The study was approved by the Medical Ethics
Committee of the Isala clinics.
After balloon placement, patients were followed
monthly for the first 6 months. They were admitted
after 6 months for balloon removal under general anes-
thesia, and during the same general anesthetic, laparo-
scopic gastric banding was performed. Then patients
were followed on an outpatient basis by the investiga-
tor and the dietician every 3 months for the first year.
Successful weight loss with the balloon was defined as
10% weight loss in the first 6 months. Successful
weight loss with the subsequent gastric banding was
defined as a 15% weight loss in the ensuing 12 months. 
Patients were divided in two groups; group A con-
sisted of patients who lost ≥10% of their starting
weight in 6 months with the intragastric balloon; group
B had a more limited success with the balloon, a loss
of <10% of their starting weight. All patients were ana-
lyzed 18 months after the entire treatment protocol.
Technique
Balloon Procedure
The procedure has been described in detail
before.3,4,12,17,18 The BioEnterics Intragastric bal-
loon (BIB® Allergan, Santa Barbara, CA, USA) was
inserted under fluoroscopic control and with the
patient sitting on a table, conscious and cooperating.
The BIB was filled with 500 ml of saline stained
with methylene blue. Methylene blue served as a
marker for balloon rupture by subsequent blue col-
oring of the urine. Six months later, the patient was
admitted to the hospital and under general anesthe-
sia the balloon was removed endoscopically by
puncturing and grasping with a forceps. After a
repeat endoscopy to deflate the stomach and to rule
out balloon-induced mucosal injury, gastric banding
surgery was performed.
In the 6 months of balloon treatment, no adjust-
ments of balloon volume, albeit feasible, were done.
However, when patients complained of blue color in
the urine, a plain abdominal X-ray was done to
check if the balloon was still fully filled and in the
stomach. When in doubt, a repeat endoscopy was
performed to check the balloon and, if necessary, to
replace the balloon by a new one. 
Laparoscopic Surgical Procedure 
The procedure of the LAGB has been described pre-
viously,6,19,20 with subsequent changes in the tech-
nique to prevent pouch formation.21 The patient was
placed in lithotomy position with the knees and hips
slightly flexed. Using 4 trocars, the band (Lap-band®
9.75 or 11 cm, Allergan, Santa Barbara, CA, USA)
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Table 1. Inclusion criteria for the study
Low probability of success with non-surgical measures
BMI >40 or BMI >35 with high-risk co-morbidities 
Age > 18 yrs < 55 yrs
Not pregnant
No prior bariatric surgery
Suitable candidate according to psychologist
No large hiatal hernia
No severe gastroesophageal reflux
No use of anticoagulants, aspirin and NSAIDs
was placed around the stomach through the pars flac-
cida approach from the base of the right crus along the
left crus to the angle of His.21 At least four ventral gas-
trogastric stitches were placed over the band to pre-
vent slippage of the distal stomach upwards through
the band. Through the xiphoid trocar-site, the tube
was pulled out and tunnelled subcutaneously to the
sternum where the port was implanted. The band was
left empty for at least 6 weeks, and the patient fol-
lowed a fluid diet to prevent slippage of the stomach.
After 6 weeks, the patient was allowed to eat every-
thing, guided by the dietician as to energy intake.
If weight loss levelled off, the band was inflated by
puncture of the port and injection of saline. The first
attempt was always done under fluoroscopic control.
All but one patient had the balloon removed and the
band placed, under the same general anesthetic.
Endpoints
The primary end-points were weight loss and BMI
1 year after gastric banding, including the weight
loss during the balloon treatment in all patients and
separately in group A and B patients. Secondary
end-points were complications related to balloon
placement and events related to LAGB such as peri-
and postoperative complications, hospital stay,
long-term complications, additional procedures, re-
admissions, band adjustments, and weight loss and
BMI reduction 1 year after gastric banding alone.
Statistical Analysis
Based on previous studies in our hospital with BIB17
starting from a hypothetical 75% success rate of a bal-
loon (success defined as ≥10% initial weight loss) and
thus a 25% balloon failure rate, and a 50% success or
failure rate of LAGB (with each a 75% success rate
and 25% failure rate in the balloon arm), a power
analysis (α of <0.05, power (1 - β) 0.80) resulted in a
number to treat of 38 patients in order to detect a sig-
nificant difference in weight loss in patients who had
6 months of preoperative treatment with the BIB fol-
lowed by 12 months of LAGB. Descriptive data are
given as means ± standard deviation (SD). Student t-
test (and Mann-Whitney U test for non-Gaussian data)
was used to compare group A and B patients. Weight




From March 1999 until February 2002, 46 consecutive
patients (9M/37F)  fulfilled the inclusion criteria. Six
patients (1M/5F) had to be excluded from the study
because of balloon-related problems and subsequent
refusal of the gastric banding procedure. In the remain-
ing 40 patients, there were eight men and 32 women
with mean age 36.6 yr (range 26-54 yr), mean weight
142.4 kg (range 111-204 kg) and mean BMI 46.5
kg/m2 (range 38.9-61.7 kg/m2). Mean excess weight
(EW) was 65.8% (range 42.9 to 110.4%) (Table 2).
Co-morbidities consisted of cardiovascular problems
(7.5%), pulmonary problems (30%), diabetes type 2
(10%), hypertension (27.5%) and osteoarthritis (70%). 
Intragastric Balloon and Gastric Band 
Removal of the BIB took on average 25 minutes
(mean 35.8 ± 19.2 SD minutes) (Table 3). In one
patient, the band was placed 3 days later because the
removal of the balloon took too long (135 minutes).
In four patients, no balloon was discovered upon
endoscopy, and none of these patients reported hav-
ing seen blue coloring of the urine. In one patient, a
second balloon was placed because of suspected
leakage and passage into the small intestine. When
this balloon was removed, the first balloon appeared
to be still present in the stomach.
The positioning of the gastric band took 104 min-
utes ± 50.2 minutes, with no mortality. Hospital stay
averaged 5.1 days (range 3-10 days). 
Major complications requiring re-operation were
seen in five patients (12.5%). In three patients, gas-
tric slippage occurred, which required re-operation
to reposition the band. Two patients developed
pouch dilatation, 14 and 20 months, after the opera-
tion, respectively. One band was repositioned via
laparotomy. The second band was removed due to a
severe metabolic derangement in a patient with
alcohol abuse and doubtful cooperation. 
Minor complications occurred in 12 patients
(26%): an abdominal hematoma at the left trocar
site, treated conservatively; conversion to a laparo-
tomy, because of left liver lobe hypertrophy in three
patients; one persistent postoperative vomiting due
to edema of the stomach, treated conservatively; one
infection from the saline used to fill the band,
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resolved with local antibiotics; twice an endoscopy
because of food retention above the band; three
times a symptomatic cholelithiasis, treated with an
uneventful laparoscopic cholecystectomy; and once
a myocardial infarction treated with a coronary
angioplasty. Because of successful weight reduc-
tion, three patients underwent an abdominoplasty.
Outcome
In the entire group, the mean BMI during balloon
treatment declined from 46.5 kg/m2 to 40.5 kg/m2
(P<0.001) after a mean treatment of 194 days ± 12
days, with an excess weight loss (EWL) of 28.7%.
The mean BMI declined further from 40.5 kg/m2 to
35.2 kg/m2 (P<0.001) 12 months after LAGB with a
EWL of 57.1% (Table 4).
Group A consisted of 25 patients with 10% initial
weight loss after 6 months balloon treatment. Group
B consisted of 15 patients with <10% initial weight
loss. Patient characteristics of groups A and B were
not different at the start for age (35.8 vs 36.3 yr),
weight (141.2 vs 144.4 kg), BMI (47.0 vs 45.6
kg/m2) and excess weight (66.0 vs 65.6%).
However, significantly more subjects in group B
suffered from diabetes type 2 (P=0.02) (Table 2). 
After 6 months of BIB treatment and 12 months of
LAGB, there was a significant difference (P<0.05) in
BMI reduction between group A (12.4 kg/m2) and
group B (9.0 kg/m2) (Table 4). Weight loss had a
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Table 2. Patient characteristics and co-morbidity of all patients, group A losing ≥10%, and group B losing <10%
of initial weight after 6 months of balloon treatment
All patients Group A Group B P-value
No. of patients 40 (8 M/ 32F) 25 (3 M/22 F) 15 (5 M/10 F)
Age (yrs) 36.6 ± 5.7 35.8 ± 6.3 36.3 ± 4.7 0.79
Weight (kg) 142.4 ± 25.5 141.2 ± 21.0 144.4 ± 32.3 0.71
BMI (kg/m2) 46.5 ± 5.7 47.0 ± 6.6 45.6 ± 4.0 0.45
% excess weight 65.8 ± 19.4 66.0 ± 19.2 65.6 ± 20.4 0.96
Cardiovascular problems 3 (7.5%) 1 2 0.72
Pulmonary problems 12(30%) 6 6 0.53
Diabetes mellitus 4 (10%) 0 4 0.02
Hypertension 11 (27.5%) 5 6 0.36
Arthrosis 28 (70%) 16 12 0.87
Table 3. Peri- and postoperative complications and events after gastric banding
Complication No. of patients Treatment
Abdominal hematoma 1 (3%) Conservative
Stomach slippage 3 (8%) Repositioning band
Pouch dilatation 2 (5%) Re-operation
Emptying problems 1 (3%) Conservative
Port infection 1 (3%) Conservative
Total 8 (17%)
Event No. of patients Treatment
Left liver lobe hypertrophy 3 (8%) Conversion 
Food retention 2 (5%) Gastroscopy
Myocardial infarction 1 (3%) Coronary angioplasty
Cholelithiasis 3 (8%) Laparoscopic cholecystectomy
Redundant pannus 3 (8%) Abdominoplasty
Total 12 (26%)
trend (P=0.07) in favor of group A (A 37.3 kg vs B
28.7 kg). The 12-month period of gastric banding
resulted in a BMI reduction of 4.7 kg/m2 in group A
vs 5.8 kg/m2 in group B, and a weight loss of 13.8
kg in group A vs 18.6 kg in group B (not different
between group A and B, P=0.35 and 0.22, respec-
tively). This was also true for the mean EWL of
32.9% vs 33.8 % (P=0.91). There was no significant
difference between the two groups with respect to
the period of the gastric band (Figure 1 and 2). The
overall difference in BMI appears to be related to the
initial weight-reducing effect of the BIB.
Balloon complications and surgical complications
peri- and postoperatively were not statistically dif-
ferent in both groups (P=0.40, 0.60 and 0.30,
respectively) (Table 4).
In group A (25 patients), there were 6 patients
who not only lost ≥10% of their initial weight dur-
ing the balloon treatment, but also lost ≥15% of
their starting weight in the following 12 months;
however, 19 patients did not lose the 15% in the 12
months of LAGB. In group B (15 patients), 9
patients were unsuccessful in both treatment peri-
ods; 6 patients were unsuccessful in the balloon
period, but lost ≥15% of their starting weight in the
following 12 months (Table 5a). The positive pre-
dictive value of the balloon was 32% and the nega-
tive predictive value of the balloon was 60%.
When we added the required ≥10% weight loss
for a successful BIB outcome to the 15% required
for a successful bariatric surgery outcome (thus,
resulting in successful weight loss of 25% for the
study duration), there were 14 successful patients vs
4 unsuccessful ones in group A. In group B, 11
patients were successful and 11 were not. This
improved the positive predictive value of the bal-
loon to 56% and the negative predictive value of the
balloon to 73% (Table 5b).
Discussion
This study found that both BIB and LAGB can be
performed safely, without mortality and with an
acceptable rate of complications. The weight reduc-
tion (30% EWL/ 6 months, 57% EWL/ 18 months)
is in accordance with other large series of balloon
and band treatment.3,17,18,22,23
de Goederen-van der Meij et al
92 Obesity Surgery, 17, 2007
Table 4. Follow-up after 6-months BIB followed by 12-months LAGB in all patients, group A losing ≥10% and
group B losing <10% of initial weight in 6 months of BIB treatment (mean ± SD)
All patients Group A Group B P-value
n=40 n=25 n=15
Body weight (kg) after 6 m BIB 124.1 ± 21.9 117.7 ± 19.2 134.7 ± 30.0 0.04
BMI (kg/m2) after 6 m BIB 40.5 ± 5.6 39.2 ± 6.3 42.5 ± 3.7 0.07
Body weight (kg) after BIB + LAGB 109.0 ± 22.6 103.9 ± 16.6 118.0 ± 29.1 0.06
BMI (kg/m2) after BIB + LAGB 35.4 ± 5.0 34.6 ± 5.1 36.7 ± 4.6 0.20
Δ Body weight with BIB 18.3 ± 10.1 23.5 ± 9.2 9.7 ± 3.8 <0.001
Δ BMI with BIB 6.0 ± 3.3 7.8 ± 2.9 3.0 ± 1.0 <0.001
Δ %EWL* with BIB 28.7 ± 15.5 36.9 ± 13.8 15.0 ± 5.0 <0.001
Δ Body weight with LAGB 10.5 ± 7.0 13.8 ± 11.3 18.6 ± 11.7 0.22
Δ BMI with LAGB 6.0 ± 6.9 4.7 ± 3.8 5.8 ± 3.6 0.35
Δ %EWL* with LAGB 28.4 ± 36.5 32.9 ± 25.9 33.8 ± 19.6 0.91
Δ Body weight with BIB + LAGB 36.1 ± 18.5 37.3 ± 14.4 28.7 ± 12.2 0.07
Δ BMI with BIB + LAGB 12.0 ± 6.9 12.4 ± 4.8 9.0 ± 3.6 0.03
Δ %EWL* with BIB + LAGB 57.1 ± 1.5 57.1 ± 19.2 56.9 ± 52.2 0.99
BIB treatment ± days 194 ± 12.0 195.2 ± 13.1 190.9 ± 10.5 0.29
Hospital stay for LAGB ± days 5. 1 ± 1.5 5.3 ± 1.3 5.3 ± 2.5 0.98
BIB complications 5 4 1 0.40
Peri-operative complications 4 3 1 0.60
Postoperative complications 12 9 3 0.30
*Using Metropolitan Life formula, 1983. Δ = delta = change in.
However, the hypothesis of the BIB being predic-
tive for successful LAGB had to be rejected, when
defining a weight loss of 10% in the first 6 months of
balloon treatment as successful and requiring a
weight loss of an additional 15% in the 12 months
following LAGB surgery. A problem with our defi-
nition could be that we did not take into account  that
losing ≥10% during the first 6 months may make it
more difficult to lose another 15% after banding.
That this might be the case is reflected by the fact
that there is a difference in the loss of weight, BMI
and % excess weight after 18 months compared to
the loss in weight, BMI and % excess weight after 12
months treatment with the band alone (Table 4). 
The weight loss difference between the two
groups after 6 months treatment with the balloon
was preserved in time, because this difference did
not diverge any further after the LAGB procedure
(Figures 1 and 2). Thus, if a patient is unsuccessful
with the balloon, he/she can still be successful in
losing weight after banding. Longer follow-up is
needed to see whether the weight difference will
persist or diminish.14 A criticism may be that the
less successful group had more diabetic patients
who may have more difficulty losing weight. When
we compare our study with large series, there tends
to be a higher percentage of patients with diabetes
(33-75%)24 and a much lower number with
osteoarthritis (12%).25
The intolerance to the BIB (11%) is relatively high
compared to the literature (6%),4,22 but adjustments
to reduce the balloon volume were not performed.
LAGB appeared to be a safe method, and no
major complications occurred in this study.
Operative time decreased with increasing experi-
ence. Length of hospital stay was 5 days and com-
pared favorably to other bariatric operations. 
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Table 5a. Number of patients who lost ≥10% of ini-
tial weight after 6 months balloon treatment and
≥15% of their intial weight 12 months after gastric
banding
BIB >15% in <15% in 
12 months 12 months
LAGB LAGB
≥10 % at 6 months 6 19
<10 % at 6 months 6 9
Table 5b. Number of patients who lost ≥10% of ini-
tial weight after 6 months balloon treatment and
≥25% of initial weight after 18 months, consisting of
6 months balloon and 12 months LAGB
BIB >25% in <25% in
18 months 18 months
≥10 % at 6 months 14 11
<10 % at 6 months 4 11





























Figure 1. Total weight loss after 6 months BIB plus 12
months LAGB (SD) of the total group, group A (≥10% WL)
and group B (<10% WL) after 6 months BIB.





















Figure 2. Total BMI reduction after 6 months BIB plus 12
months LAGB (SD) of the total group, group A (≥10% WL)
























Changes in BMI and weight in patients who under-
went LAGB after a 6-month preoperative placement
of a gastric balloon, appeared not to be predicted by
the results obtained with the balloon. The greater
loss of BMI in the successful balloon-treated group
was maintained through the 1st year after surgery.
Pre-treatment with BIB could be more relevant for
super-obese patients anesthesiologically.
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